Document is current
Any future updates will be listed below
-
Authors
Lecocq, Q. http://orcid.org/0000-0002-2627-0880
Debie, P. http://orcid.org/0000-0002-9128-7814
Puttemans, J. http://orcid.org/0000-0003-3753-1895
Awad, R. M. http://orcid.org/0000-0001-5434-494X
De Beck, L. http://orcid.org/0000-0002-8445-0441
Ertveldt, T. http://orcid.org/0000-0001-7825-7808
De Vlaeminck, Y. http://orcid.org/0000-0002-1882-4740
Goyvaerts, C. http://orcid.org/0000-0002-1725-7772
Raes, G. http://orcid.org/0000-0002-9065-1549
Keyaerts, M. http://orcid.org/0000-0002-9997-4571
Breckpot, K. http://orcid.org/0000-0003-4331-3480
Devoogdt, N. http://orcid.org/0000-0001-9220-4833
-
Funding
Funding for this research was provided by:
FWO (1S24218N, 1S05022N, 1S06622N, 1142819N, 1801619N, 1501019N)
Kom op tegen Kanker
- License Information
-
More Information
Article History
Received: 11 August 2021
Accepted: 22 October 2021
First Online: 2 November 2021
Declarations
:
: Not applicable.
: Approval by the Ethical Committee for Laboratory Animals of the Vrije Universiteit Brussel was granted prior to execution of the experiments under ethical dossier/protocol 15-214-1. All animal studies were performed according to the European guidelines for animal experimentation.
: N. Devoogdt and G. Raes are shareholders and consultants of, and M. Keyaerts received research funding from Precirix® (formerly named Camel-IDS). Q. Lecocq, K. Breckpot, N. Devoogdt and M. Keyaerts have patent applications on the use of single domain antibodies for immune-checkpoint imaging and therapy (WO2019166622 and EP20020653). N. Devoogdt, M. Keyaerts and G. Raes have ownership in AbScint, which leverages sdAb imaging tracers into clinical application. No other potential conflicts of interest relevant to this article exist.
